Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)

Clinical Trial ID NCT01147211

Rank	Title	Journal	Year	PubWeight™‹?›
1	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.	Oncotarget	2012	1.96
2	Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.	Clin Cancer Res	2014	1.33
3	Molecular pathways and therapeutic targets in lung cancer.	Oncotarget	2014	1.16
4	EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.	Am J Cancer Res	2014	1.08
5	Novel agents and strategies for overcoming EGFR TKIs resistance.	Exp Hematol Oncol	2014	1.01
6	Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment.	Lung Cancer Manag	2014	0.93
7	Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.	Oncotarget	2014	0.91
8	Targeting genomic alterations in squamous cell lung cancer.	Front Oncol	2013	0.85
9	Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer.	Onco Targets Ther	2013	0.85
10	Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials.	Curr Oncol	2012	0.81
11	The Biological Role of PI3K Pathway in Lung Cancer.	Pharmaceuticals (Basel)	2012	0.81